FENC Annual ROE
138.06%
+497.28%+138.43%
31 December 2023
Summary:
As of January 21, 2025, FENC annual return on equity is 138.06%, with the most recent change of +497.28% (+138.43%) on December 31, 2023. During the last 3 years, it has risen by +226.52% (+256.07%). FENC annual ROE is now -13.10% below its all-time high of 158.87%, reached on December 31, 2010.FENC ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
FENC Quarterly ROE
29.94%
+83.32%+156.09%
30 September 2024
Summary:
As of January 21, 2025, FENC quarterly return on equity is 29.94%, with the most recent change of +83.32% (+156.09%) on September 30, 2024. Over the past year, it has increased by +83.32% (+156.09%). FENC quarterly ROE is now -99.60% below its all-time high of 7463.86%, reached on June 30, 2012.FENC Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
FENC ROE Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +138.4% | +156.1% |
| 3 y3 years | +256.1% | +103.2% |
| 5 y5 years | +435.6% | +103.2% |
FENC ROE High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +138.4% | -95.2% | +103.2% |
| 5 y | 5-year | at high | +138.4% | -95.2% | +103.2% |
| alltime | all time | -13.1% | +103.5% | -99.6% | +101.0% |
Fennec Pharmaceuticals ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | 29.94%(-156.1%) |
| June 2024 | - | -53.38%(+35.4%) |
| Mar 2024 | - | -39.41%(-124.1%) |
| Dec 2023 | 138.06%(-138.4%) | 163.65%(-39.0%) |
| Sept 2023 | - | 268.12%(-57.3%) |
| June 2023 | - | 628.34%(-167.3%) |
| Mar 2023 | - | -933.81%(+192.0%) |
| Dec 2022 | -359.22%(+364.3%) | -319.85%(+76.3%) |
| Sept 2022 | - | -181.44%(+63.1%) |
| June 2022 | - | -111.22%(+28.9%) |
| Mar 2022 | - | -86.27%(+10.5%) |
| Dec 2021 | -77.37%(-12.5%) | -78.09%(+22.3%) |
| Sept 2021 | - | -63.87%(+0.9%) |
| June 2021 | - | -63.28%(-13.6%) |
| Mar 2021 | - | -73.27%(-5.6%) |
| Dec 2020 | -88.46%(+14.9%) | -77.58%(-13.8%) |
| Sept 2020 | - | -90.02%(+12.4%) |
| June 2020 | - | -80.11%(-18.6%) |
| Mar 2020 | - | -98.39%(+29.2%) |
| Dec 2019 | -76.99%(+87.1%) | -76.16%(+18.9%) |
| Sept 2019 | - | -64.04%(+2.5%) |
| June 2019 | - | -62.50%(+30.1%) |
| Mar 2019 | - | -48.05%(+18.0%) |
| Dec 2018 | -41.14%(-11.5%) | -40.71%(-3.5%) |
| Sept 2018 | - | -42.18%(-8.1%) |
| June 2018 | - | -45.91%(-13.2%) |
| Mar 2018 | - | -52.89%(-22.3%) |
| Dec 2017 | -46.47%(-65.7%) | -68.11%(-32.6%) |
| Sept 2017 | - | -101.05%(+24.7%) |
| June 2017 | - | -81.04%(-20.6%) |
| Mar 2017 | - | -102.11%(-3.1%) |
| Dec 2016 | -135.45%(+19.3%) | -105.37%(+3.0%) |
| Sept 2016 | - | -102.31%(-14.2%) |
| June 2016 | - | -119.27%(-28.8%) |
| Mar 2016 | - | -167.56%(+109.4%) |
| Dec 2015 | -113.52%(-68.0%) | -80.01%(-104.3%) |
| Sept 2015 | - | 1855.26%(-277.2%) |
| June 2015 | - | -1046.97%(+1312.2%) |
| Mar 2015 | - | -74.14%(-198.9%) |
| Dec 2014 | -354.98%(+180.0%) | 74.99%(+4.5%) |
| Sept 2014 | - | 71.75%(-43.2%) |
| June 2014 | - | 126.22%(-241.2%) |
| Mar 2014 | - | -89.36%(+106.9%) |
| Dec 2013 | -126.80%(-221.7%) | -43.20%(-138.5%) |
| Sept 2013 | - | 112.31%(-10.8%) |
| June 2013 | - | 125.96%(-71.9%) |
| Mar 2013 | - | 448.33%(-114.7%) |
| Dec 2012 | 104.16% | -3047.23%(-367.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2012 | - | 1138.24%(-84.7%) |
| June 2012 | - | 7463.86%(-1122.8%) |
| Mar 2012 | - | -729.75%(+61.3%) |
| Dec 2011 | -3904.17%(-2557.5%) | -452.36%(-329.6%) |
| Sept 2011 | - | 197.01%(-1750.0%) |
| June 2011 | - | -11.94%(-104.4%) |
| Mar 2011 | - | 273.43%(-67.2%) |
| Dec 2010 | 158.87%(-191.2%) | 833.45%(-414.5%) |
| Sept 2010 | - | -264.99%(-85.7%) |
| June 2010 | - | -1846.93%(+661.0%) |
| Mar 2010 | - | -242.71%(-13.9%) |
| Dec 2009 | -174.15%(+10.1%) | -281.76%(-1.0%) |
| Sept 2009 | - | -284.55%(+12.7%) |
| June 2009 | - | -252.56%(+25.5%) |
| Mar 2009 | - | -201.30%(+23.5%) |
| Dec 2008 | -158.13%(-8.7%) | -163.04%(+28.0%) |
| Sept 2008 | - | -127.37%(+27.1%) |
| June 2008 | - | -100.25%(+20.3%) |
| Mar 2008 | - | -83.36%(-9.9%) |
| Dec 2007 | -173.29%(-3.3%) | -92.48%(-25.2%) |
| Sept 2007 | - | -123.62%(-4.9%) |
| June 2007 | - | -130.01%(-7.0%) |
| Mar 2007 | - | -139.86%(+3.2%) |
| Dec 2006 | -179.16%(+147.0%) | -135.53%(+38.6%) |
| Sept 2006 | - | -97.78%(+10.7%) |
| June 2006 | - | -88.35%(+3.2%) |
| Mar 2006 | - | -85.59%(+14.2%) |
| Dec 2005 | -72.54%(+100.6%) | -74.93%(+41.2%) |
| Sept 2005 | - | -53.06%(+13.9%) |
| June 2005 | - | -46.59%(+26.7%) |
| Mar 2005 | - | -36.78%(+0.6%) |
| Sept 2004 | - | -36.55%(+0.4%) |
| June 2004 | -36.17%(-37.1%) | -36.40%(-9.8%) |
| Mar 2004 | - | -40.36%(-3.8%) |
| Dec 2003 | - | -41.95%(-17.4%) |
| Sept 2003 | - | -50.76%(-5.2%) |
| June 2003 | -57.46%(+22.9%) | -53.52%(-4.3%) |
| Mar 2003 | - | -55.92%(+1.5%) |
| Dec 2002 | - | -55.08%(-5.0%) |
| Sept 2002 | - | -57.97%(+22.7%) |
| June 2002 | -46.77%(-6.0%) | -47.25%(+23.6%) |
| Mar 2002 | - | -38.22%(+6.6%) |
| Dec 2001 | - | -35.87%(+0.5%) |
| Sept 2001 | - | -35.70%(+9.3%) |
| June 2001 | -49.76%(-98.5%) | -32.66%(-0.8%) |
| Mar 2001 | - | -32.93%(+72.8%) |
| Dec 2000 | - | -19.06% |
| June 2000 | -3420.34% | - |
FAQ
- What is Fennec Pharmaceuticals annual return on equity?
- What is the all time high annual ROE for Fennec Pharmaceuticals?
- What is Fennec Pharmaceuticals annual ROE year-on-year change?
- What is Fennec Pharmaceuticals quarterly return on equity?
- What is the all time high quarterly ROE for Fennec Pharmaceuticals?
- What is Fennec Pharmaceuticals quarterly ROE year-on-year change?
What is Fennec Pharmaceuticals annual return on equity?
The current annual ROE of FENC is 138.06%
What is the all time high annual ROE for Fennec Pharmaceuticals?
Fennec Pharmaceuticals all-time high annual return on equity is 158.87%
What is Fennec Pharmaceuticals annual ROE year-on-year change?
Over the past year, FENC annual return on equity has changed by +497.28% (+138.43%)
What is Fennec Pharmaceuticals quarterly return on equity?
The current quarterly ROE of FENC is 29.94%
What is the all time high quarterly ROE for Fennec Pharmaceuticals?
Fennec Pharmaceuticals all-time high quarterly return on equity is 7463.86%
What is Fennec Pharmaceuticals quarterly ROE year-on-year change?
Over the past year, FENC quarterly return on equity has changed by +83.32% (+156.09%)